Results 61 to 70 of about 2,368,340 (74)

Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.

Pharmacology and Therapeutics, 2017
H. Patel, Teeru Bihani
semanticscholar   +1 more source

Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription

Cell, 2000
Yongfeng Shang, Xiao Hu, J. Direnzo, M. Lazar, Myles A. Brown   +4 more
semanticscholar   +1 more source

Estrogen receptor beta in breast cancer

Molecular and Cellular Endocrinology, 2014
L. Haldosen, Chunyan Zhao, K. Dahlman-Wright   +2 more
semanticscholar   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.

Journal of Medicinal Chemistry, 2018
In breast cancer, estrogen receptor alpha (ERα) positive cancer accounts for approximately 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation.
G. Tria, T. Abrams, J. Baird, H. Burks, B. Firestone, L. Gaither, L. Hamann, Guo He, C. Kirby, Sunkyu Kim, F. Lombardo, Kaitlin J Macchi, D. McDonnell, Y. Mishina, J. Norris, Jill Nunez, C. Springer, Yingchuan Sun, Noel M. Thomsen, Chunrong Wang, Jianling Wang, Bing Yu, Choi-Lai Tiong-Yip, S. Peukert   +23 more
semanticscholar   +1 more source

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Journal of Clinical Oncology, 2006
PURPOSE The 21-gene recurrence score (RS) assay quantifies the likelihood of distant recurrence in women with estrogen receptor-positive, lymph node-negative breast cancer treated with adjuvant tamoxifen.
S. Paik, G. Tang, S. Shak, Chungyeul Kim, J. Baker, W. Kim, M. Cronin, F. Baehner, D. Watson, J. Bryant, J. Costantino, C. Geyer, D. Wickerham, N. Wolmark   +13 more
semanticscholar   +1 more source

Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase

Science, 1995
The phosphorylation of the human estrogen receptor (ER) serine residue at position 118 is required for full activity of the ER activation function 1 (AF-1).
S. Kato, H. Endoh, Y. Masuhiro, T. Kitamoto, Shimami Uchiyama, H. Sasaki, S. Masushige, Y. Gotoh, E. Nishida, H. Kawashima, D. Metzger, P. Chambon   +11 more
semanticscholar   +1 more source

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.

Journal of Medicinal Chemistry, 2015
Approximately 80% of breast cancers are estrogen receptor alpha (ER-α) positive, and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.
Andiliy G. Lai, M. Kahraman, S. Govek, Johnny Y. Nagasawa, C. Bonnefous, J. Julien, Karensa L Douglas, J. Sensintaffar, Nhin Lu, Kyoung-jin Lee, Anna Aparicio, Josh Kaufman, J. Qian, G. Shao, R. Prudente, Michael J Moon, James D. Joseph, B. Darimont, D. Brigham, Kate Grillot, R. Heyman, P. Rix, J. Hager, N. Smith   +23 more
semanticscholar   +1 more source

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Archives of Pathology & Laboratory Medicine, 2010
PURPOSE To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers.
M. E. Hammond, Daniel F. Hayes, M. Dowsett, D. Allred, K. Hagerty, S. Badve, P. Fitzgibbons, G. Francis, Neil S. Goldstein, M. Hayes, David G. Hicks, S. Lester, R. Love, P. Mangu, L. McShane, K. Miller, C. K. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, Jared N. Schwartz, F. C. Sweep, S. Taube, E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. B. Williams, J. Wittliff, Antonio C. Wolff   +31 more
semanticscholar   +1 more source

Estrogen Receptor

Encyclopedia of Pathology, 2021
Irene Porcari, Mariachiara Bosco, S. Uccella   +2 more
semanticscholar   +1 more source

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

New England Journal of Medicine, 1989
We conducted a randomized, double-blind, placebo-controlled trial of postoperative therapy with tamoxifen (10 mg twice a day) in 2644 patients with breast cancer, histologically negative axillary nodes, and estrogen-receptor-positive (greater than or ...
B. Fisher, J. Costantino, C. Redmond, R. Poisson, D. Bowman, J. Couture, N. Dimitrov, N. Wolmark, D. Wickerham, Edwin R. Fisher, R. Margolese, A. Robidoux, H. Shibata, J. Terz, A. Paterson, M. Feldman, W. Farrar, James Evans, H. Lickley, Mary Ketner   +19 more
semanticscholar   +1 more source